Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. In: Archives of Ophthalmology (Chicago, Ill.: 1960). Band119, Nr.10, Oktober 2001, S.1417–1436, doi:10.1001/archopht.119.10.1417, PMID 11594942, PMC 1462955 (freier Volltext) – (englisch).
Johanna M. Seddon et al.: Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. In: The British Journal of Ophthalmology. Band100, Nr.12, Dezember 2016, S.1731–1737, doi:10.1136/bjophthalmol-2016-308624, PMID 27471039, PMC 6570490 (freier Volltext) – (englisch).
Demetrios G. Vavvas et al.: CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. In: Proceedings of the National Academy of Sciences of the United States of America. Band115, Nr.4, 23. Januar 2018, S.E696–E704, doi:10.1073/pnas.1718059115, PMID 29311295, PMC 5789949 (freier Volltext) – (englisch).
Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. In: JAMA. Band309, Nr.19, 15. Mai 2013, S.2005–2015, doi:10.1001/jama.2013.4997, PMID 23644932 (englisch).
Jennifer R. Evans, John G. Lawrenson: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. In: The Cochrane Database of Systematic Reviews. Band7, 31. Juli 2017, S.CD000254, doi:10.1002/14651858.CD000254.pub4, PMID 28756618, PMC 6483465 (freier Volltext) – (englisch).
nih.gov
ncbi.nlm.nih.gov
Age-Related Eye Disease Study Research Group: A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. In: Archives of Ophthalmology (Chicago, Ill.: 1960). Band119, Nr.10, Oktober 2001, S.1417–1436, doi:10.1001/archopht.119.10.1417, PMID 11594942, PMC 1462955 (freier Volltext) – (englisch).
Johanna M. Seddon et al.: Response to AREDS supplements according to genetic factors: survival analysis approach using the eye as the unit of analysis. In: The British Journal of Ophthalmology. Band100, Nr.12, Dezember 2016, S.1731–1737, doi:10.1136/bjophthalmol-2016-308624, PMID 27471039, PMC 6570490 (freier Volltext) – (englisch).
Demetrios G. Vavvas et al.: CFH and ARMS2 genetic risk determines progression to neovascular age-related macular degeneration after antioxidant and zinc supplementation. In: Proceedings of the National Academy of Sciences of the United States of America. Band115, Nr.4, 23. Januar 2018, S.E696–E704, doi:10.1073/pnas.1718059115, PMID 29311295, PMC 5789949 (freier Volltext) – (englisch).
Age-Related Eye Disease Study 2 Research Group: Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. In: JAMA. Band309, Nr.19, 15. Mai 2013, S.2005–2015, doi:10.1001/jama.2013.4997, PMID 23644932 (englisch).
Jennifer R. Evans, John G. Lawrenson: Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. In: The Cochrane Database of Systematic Reviews. Band7, 31. Juli 2017, S.CD000254, doi:10.1002/14651858.CD000254.pub4, PMID 28756618, PMC 6483465 (freier Volltext) – (englisch).